Epigral Ltd (EPIGRAL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003523, "name": "Epigral", "stock_name": "Epigral", "full_name": "Epigral Ltd", "name_url": "stocks-analysis/epigral", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,121.00", "chg": 19.3, "chgp": "1.75%", "dir": 1, "prev_price": "1,101.70", "mcapval": "4,836.14 Cr", "mcap": "Small Cap", "scripcode": 543332, "symbol": "EPIGRAL", "ind_name": "Specialty Chemicals", "ind_code": 11, "sector_id": 74, "indexname": "India SENSEX", "isin": "INE071N01016", "curr_date": "Aug 10, 10:39 AM", "curr_time": "10:41 AM", "last_traded_at": "Aug 10, 10:39 AM IST", "bse_nse_vol": "13.83 k", "exc_status": "Active", "traded_date": "Aug 10, 2026", "traded_date_str": "2026 08 10", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/epigral-1003523-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Epigral Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/epigral-ltd-is-rated-sell-by-marketsmojo-4142881", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/EpigralLtd_mojoScore_4142881.png", "date": "2026-08-08 10:10:16", "description": "Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 August 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Epigral Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/epigral-ltd-technical-momentum-shifts-amid-mixed-market-signals-4135381", "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/EpigralLtd_technicaldot_4135381.png", "date": "2026-08-04 08:10:22", "description": "Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish trend. Despite a recent day gain of 2.59%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, reflecting cautious investor sentiment amid broader market challenges." }, { "title": "Epigral Ltd Falls 6.28%: Four Key Factors Shaping This Week’s Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/epigral-ltd-falls-628-four-key-factors-shaping-this-weeks-decline-4131402", "imagepath": "", "date": "2026-08-01 12:01:13", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Jul:</strong> Q1 FY27 profit rebounds 23% despite revenue dip and margin pressures</p>\n <p><strong>28 Jul:</strong> Stabilised quarterly performance amid mixed financial indicators</p>\n <p><strong>29 Jul:</strong> Valuation shifts from attractive to fair amid sector dynamics</p>\n <p><strong>31 Jul:</strong> Technical momentum shifts amid bearish signals</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,163.05</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Clo..." }, { "title": "Epigral Ltd Technical Momentum Shifts Amid Bearish Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/epigral-ltd-technical-momentum-shifts-amid-bearish-signals-4129587", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/EpigralLtd_technicaldot_4129587.png", "date": "2026-07-31 08:02:52", "description": "Epigral Ltd, a small-cap player in the specialty chemicals sector, has experienced a notable shift in its technical momentum, signalling increased bearish pressure. Despite a modest recovery in monthly MACD readings, the overall technical landscape remains challenging, with key indicators such as moving averages and KST pointing to sustained downward trends. This analysis delves into the recent technical parameter changes, price momentum, and comparative performance against the Sensex to provide a comprehensive view for investors." }, { "title": "Epigral Ltd Valuation Shifts: From Attractive to Fair Amid Specialty Chemicals Sector Dynamics", "link": "https://www.marketsmojo.com/news/stocks-in-action/epigral-ltd-valuation-shifts-from-attractive-to-fair-amid-specialty-chemicals-sector-dynamics-4125080", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/EpigralLtd_valuationdot_4125080.png", "date": "2026-07-29 08:02:20", "description": "Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid sector-wide valuation disparities and company-specific performance metrics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks." }, { "title": "Are Epigral Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-epigral-ltd-latest-results-good-or-bad-4124646", "imagepath": "", "date": "2026-07-28 19:18:25", "description": "Epigral Ltd's latest financial results for the quarter ending June 2026 reflect a complex operational landscape characterized by both sequential recovery and year-on-year challenges. The company reported net sales of ₹705.36 crores, which represents a decline of 4.18% compared to the previous quarter, breaking the momentum seen in the prior quarter's strong growth. However, year-on-year, net sales showed a notable increase of 16.29%, indicating some resilience in demand compared to the same period last year.\n\nThe net profit for the quarter was ₹99.74 crores, which marked a sequential increase of 23.21% from the previous quarter, showcasing a recovery in profitability. Nonetheless, on a year-on-year basis, net profit experienced a decline of 37.93%, largely influenced by an exceptionally strong profit base in the prior year due to tax adjustments.\n\nOperating margins improved significantly, expanding to 25.41..." }, { "title": "Epigral Ltd is Rated Sell by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/epigral-ltd-is-rated-sell-by-marketsmojo-4124207", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/EpigralLtd_mojoScore_4124207.png", "date": "2026-07-28 10:10:03", "description": "Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date view of the company’s performance and outlook." }, { "title": "Epigral Ltd Reports Stabilised Quarterly Performance Amid Mixed Financial Indicators", "link": "https://www.marketsmojo.com/news/stocks-in-action/epigral-ltd-reports-stabilised-quarterly-performance-amid-mixed-financial-indicators-4123098", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/EpigralLtd_fintrenddot_4123098.png", "date": "2026-07-28 08:00:12", "description": "Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has reported a stabilisation in its financial trend for the quarter ended June 2026, shifting from a negative trajectory to a flat performance. Despite some encouraging signs in operating profit and quarterly earnings growth, the company continues to face challenges in return on capital and cash reserves, reflecting a mixed outlook for investors." }, { "title": "Epigral Q1 FY27: Profit Rebounds 23% Despite Revenue Dip and Margin Pressures", "link": "https://www.marketsmojo.com/news/result-analysis/epigral-q1-fy27-profit-rebounds-23-despite-revenue-dip-and-margin-pressures-4123000", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/Epigral_quaterlyResult_4123000.png", "date": "2026-07-27 20:47:10", "description": "Epigral Ltd., a specialty chemicals manufacturer with a market capitalisation of ₹5,088 crores, reported a mixed performance in Q1 FY27, with consolidated net profit rising 23.21% quarter-on-quarter to ₹99.74 crores despite a 4.18% decline in net sales. The company's shares traded at ₹1,159.75 on July 27, down 37.28% over the past year, significantly underperforming the broader Sensex and the specialty chemicals sector." } ], "total": 639, "sid": "1003523", "stock_news_url": "https://www.marketsmojo.com/news/epigral-1003523" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "07-Aug-2026", "details": "Epigral Limited hereby informs that the officials of the Company are participating in EMKAY Confluence 2026 on 12th August 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "30-Jul-2026", "details": "Epigral Limited submits Transcript of Conference Call discussing Q1 FY27 Results.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "30-Jul-2026", "details": "Epigral Limited informs that the Company is having One-on-One Meeting with Investor / Analyst on Monday 3rd august 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Epigral Ltd has declared <strong>50%</strong> dividend, ex-date: 01 Jun 26", "dt": "2026-06-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

27 Jul: Q1 FY27 profit rebounds 23% despite revenue dip and margin pressures

28 Jul: Stabilised quarterly performance amid mixed financial indicators

29 Jul: Valuation shifts from attractive to fair amid sector dynamics

31 Jul: Technical momentum shifts amid bearish signals

Week Open

Rs.1,163.05

Week Clo...

Read full news article

Epigral Ltd Technical Momentum Shifts Amid Bearish Signals

2026-07-31 08:02:52

Epigral Ltd, a small-cap player in the specialty chemicals sector, has experienced a notable shift in its technical momentum, signalling increased bearish pressure. Despite a modest recovery in monthly MACD readings, the overall technical landscape remains challenging, with key indicators such as moving averages and KST pointing to sustained downward trends. This analysis delves into the recent technical parameter changes, price momentum, and comparative performance against the Sensex to provide a comprehensive view for investors.

Read full news article

Epigral Ltd Valuation Shifts: From Attractive to Fair Amid Specialty Chemicals Sector Dynamics

2026-07-29 08:02:20

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change reflects evolving market perceptions amid sector-wide valuation disparities and company-specific performance metrics, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Are Epigral Ltd latest results good or bad?

2026-07-28 19:18:25

Epigral Ltd's latest financial results for the quarter ending June 2026 reflect a complex operational landscape characterized by both sequential recovery and year-on-year challenges. The company reported net sales of ₹705.36 crores, which represents a decline of 4.18% compared to the previous quarter, breaking the momentum seen in the prior quarter's strong growth. However, year-on-year, net sales showed a notable increase of 16.29%, indicating some resilience in demand compared to the same period last year. The net profit for the quarter was ₹99.74 crores, which marked a sequential increase of 23.21% from the previous quarter, showcasing a recovery in profitability. Nonetheless, on a year-on-year basis, net profit experienced a decline of 37.93%, largely influenced by an exceptionally strong profit base in the prior year due to tax adjustments. Operating margins improved significantly, expanding to 25.41...

Read full news article

Epigral Ltd is Rated Sell by MarketsMOJO

2026-07-28 10:10:03

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Epigral Ltd Reports Stabilised Quarterly Performance Amid Mixed Financial Indicators

2026-07-28 08:00:12

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has reported a stabilisation in its financial trend for the quarter ended June 2026, shifting from a negative trajectory to a flat performance. Despite some encouraging signs in operating profit and quarterly earnings growth, the company continues to face challenges in return on capital and cash reserves, reflecting a mixed outlook for investors.

Read full news article

Epigral Q1 FY27: Profit Rebounds 23% Despite Revenue Dip and Margin Pressures

2026-07-27 20:47:10

Epigral Ltd., a specialty chemicals manufacturer with a market capitalisation of ₹5,088 crores, reported a mixed performance in Q1 FY27, with consolidated net profit rising 23.21% quarter-on-quarter to ₹99.74 crores despite a 4.18% decline in net sales. The company's shares traded at ₹1,159.75 on July 27, down 37.28% over the past year, significantly underperforming the broader Sensex and the specialty chemicals sector.

Read full news article